普罗布考对高脂血症患者血脂及氧化型低密度脂蛋白和单核细胞趋化蛋白-1的影响  

Effect of Probucol on Decreasing Blood Lipids,Oxidative Low Density Lipoprotein and Monocyte Chemo Attractant Protein-1 in Patients With Hyperlipidemia

作　　者：王敏[1] 谭茗月[1] 赵水平[1] 

机构地区：[1]中南大学湘雅二医院心血管内科,湖南省长沙市410011

出　　处：《中国循环杂志》2014年第1期31-34,共4页Chinese Circulation Journal

摘　　要：目的:评估国人服用普罗布考的降脂安全性和疗效,探讨该药对高脂血症患者氧化型低密度脂蛋白(oxLDL)和单核细胞趋化蛋白-1(MCP-1)的影响。方法:264例高脂血症患者,随机分为:普罗布考组(n=127)即服用普罗布考250 mg 2次/天;安慰剂组(n=137),服用安慰剂1片2次/次。分别于入组时、第4周和第8周采血,测定血脂、oxLDL和MCP-11血清水平,监测药物不良反应。结果:第4周和第8周:普罗布考组与同组入组时及安慰剂组同时段的总胆固醇、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)均降低,差异均有统计学意义(P均<0.001);普罗布考组第4周和第8周甘油三酯的浓度较入组时降低不明显,差异无统计学意义(P>0.05);两组间oxLDL和MCP-1浓度降低差异无统计学意义(P均>0.05);两组入组前后组间各项安全性指标无显著差异(P均>0.05)。两组治疗8周期间未见不良事件。结论 :普罗布考可显著降低中国高脂血症患者的胆固醇水平,且安全性良好。Objective： To evaluate the safety and efficacy of probucol on decreasing blood lipids, oxidative low density lipoprotein （oxLDL） and monocyte chemo attractant protein-1 （MCP-1） in patients with hyperlipidemia. Methods： A total of 264 patients were randomized into 2 groups. Probucol group, n=127, the patients were treated with probucol 250 mg twice/day and Placebo group, n=137, the patients received placebo twice/day. All patients were treated for 8 weeks. The levels of blood lipids, oxLDL and MCP-1 were examined at 0, 4 and 8 weeks after the treatment respectively, the side effect of medication was monitored in all patients. Results： With 4 and 8 weeks of treatment, the levels of TC, LDL-C and HDL-C in Probucol group were significantly decreased all P〈0.001. The TG levels at 4 and 8 weeks of treatment were similar to 0 week in Probucol group, P〉0.05. The decreasing degree of oxLDL and MCP-1 were similar between 2 groups, P〉0.05, and the safety index were similar before and after the treatment between 2 groups, P〉0.05. There were no adverse events reported in neither group during 8 weeks of treatment. Conclusion： Probucol could obviously and safely decrease the cholesterol level in patients with hyperlipidemia.

关 键 词：普罗布考 高脂血症 氧化型低密度脂蛋白 单核细胞趋化蛋白1 

分 类 号：R541[医药卫生—心血管疾病]